UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 132

Sortiert nach

ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

ANNALS OF ONCOLOGY, 2019, Vol.30, p.v354

2019

Volltextzugriff (PDF)

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting

British journal of cancer, 2013-04, Vol.108 (6), p.1358-1367

2013

Volltextzugriff (PDF)

Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

ANNALS OF ONCOLOGY, 2019, Vol.30, p.v30-v31

2019

Volltextzugriff (PDF)

Acute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer: A prospective study

Annals of oncology, 2018-10, Vol.29, p.viii631-viii632

2018

Volltextzugriff (PDF)

Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns

European urology, 2017-08, Vol.72 (2), p.192-200

2017

Volltextzugriff (PDF)

Androgen deprivation therapy in advanced prostate cancer: insights from a real-world patient survey on health-related quality of life and information and communication sources

Quality of life research, 2024-06

2024

Volltextzugriff (PDF)

Differential impact of RB status on E2F1 reprogramming in human cancer

The Journal of clinical investigation, 2018-01, Vol.128 (1), p.341-358

2018

Volltextzugriff (PDF)

Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma

PloS one, 2021-05, Vol.16 (5), p.e0251052-e0251052

2021

Volltextzugriff (PDF)

Using 68Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice

The Journal of nuclear medicine (1978), 2022-12, Vol.63 (12), p.1815-1821

2022

Volltextzugriff (PDF)

Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer

Prostate cancer and prostatic diseases, 2021-06, Vol.24 (2), p.499-506

2021

Volltextzugriff (PDF)

Has the PROPHECY of AR-V7 Been Fulfilled?

Journal of clinical oncology, 2019-08, Vol.37 (24), p.2181-2182

2019

Volltextzugriff (PDF)

HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques

PloS one, 2019-09, Vol.14 (9), p.e0220906-e0220906

2019

Volltextzugriff (PDF)

Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer

Clinical chemistry (Baltimore, Md.), 2023-04, Vol.69 (4), p.386-398

2023

Volltextzugriff (PDF)

Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorization

eLife, 2022-07, Vol.11

2022

Volltextzugriff (PDF)

896TiP - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2019-10, Vol.30, p.v354-v354

2019

Volltextzugriff (PDF)

896TiPProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1776PAcute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer: A prospective study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer

International journal of radiation oncology, biology, physics, 2023-04, Vol.115 (5), p.1095-1101

2023

Volltextzugriff (PDF)

106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

106P - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Annals of oncology, 2019-10, Vol.30, p.v30-v31

2019

Volltextzugriff (PDF)

LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

Annals of oncology, 2023-10, Vol.34, p.S1327-S1327

2023

Volltextzugriff (PDF)

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Trials, 2020-06, Vol.21 (1), p.579-10, Article 579

2020

Volltextzugriff (PDF)

EP-1597: Dose-escalation for early salvage radiotherapy in prostate cancer improves bDFS

Radiotherapy and oncology, 2018-04, Vol.127, p.S859-S860

2018

Volltextzugriff (PDF)

1 – 25 von 132

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(120)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting

Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Acute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer: A prospective study

Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Androgen deprivation therapy in advanced prostate cancer: insights from a real-world patient survey on health-related quality of life and information and communication sources

Differential impact of RB status on E2F1 reprogramming in human cancer

Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma

Using 68Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice

Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer

Has the PROPHECY of AR-V7 Been Fulfilled?

HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques

Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorization

896TiP - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

896TiPProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

1776PAcute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer: A prospective study

WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer

106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

106P - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

EP-1597: Dose-escalation for early salvage radiotherapy in prostate cancer improves bDFS

Suchergebnisse filtern